How brain bleeds in older adults affect lung health and recovery
Pathobiology of ICH in Aging
['FUNDING_R01'] · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · NIH-11285211
This project looks at whether age-related immune changes driven by the chemical CCL11 and its receptor CCR3 make brain bleeds worse and whether blocking that pathway might reduce damage in older people.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11285211 on ClinicalTrials.gov |
What this research studies
This work uses mouse models that mimic aging to study intracerebral hemorrhage (brain bleed) and related lung injury from the patient's point of view. Researchers raise levels of the immune signal CCL11 or remove CCR3 to see how lung neutrophils and brain microglia change after a bleed. They track whether CCR3-positive neutrophils move from the lung into the injured brain and whether changing CCL11/CCR3 signaling reduces brain damage and helps clear the hematoma. The goal is to reveal immune links between the lung and brain after ICH that could guide new therapies for older patients.
Who could benefit from this research
Good fit: Ideal candidates for related future trials would be older adults who have experienced an intracerebral hemorrhage and are interested in immune-targeting therapies to improve recovery.
Not a fit: People who have not had an intracerebral hemorrhage or whose problems are unrelated to lung–brain immune interactions are unlikely to benefit directly from this research.
Why it matters
Potential benefit: If successful, this work could point to new treatments that reduce brain and lung damage after intracerebral hemorrhage in older adults by targeting CCL11/CCR3-driven immune responses.
How similar studies have performed: Prior studies show CCL11 rises with age and can change immune cell behavior, but targeting CCR3 to block lung-to-brain neutrophil-driven damage after ICH remains largely preclinical and novel.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JUNG, JOO EUN — UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
- Study coordinator: JUNG, JOO EUN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired brain injury, Acute Lung Injury, Acute Pulmonary Injury